ozawade
bioprojet pharma - pitolisant - sleep apnea, obstructive - kiti nervų sistemos vaistai - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - rukuronio arba vekuronio sukeltos nervų ir raumenų blokados pasikeitimas. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuskulinė blokada - sugamadeksas - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
anagrelide mylan
mylan pharmaceuticals limited - anagrelide hidrochloridas - trombocithemija, esterinė - antinavikiniai vaistai - anagrelide yra nurodyta sumažinti padidėjęs trombocitų skaičius rizikos esminius thrombocythaemia (et) pacientams, kurie netoleruoja jų dabartinę terapija arba kurių padidėjęs trombocitų skaičius nėra sumažintas iki priimtino lygio dabartinis jų terapija. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.
influvac tetra
viatris healthcare limited - Į a/victoria/4897/2022 (h1n1)pdm09 panašios padermės (a/victoria/4897/2022 ivr‐238)/a/darwin/9/2021 (h3n2) panaši padermė (a/darwin/9/2021, san-010)/b/austria/1359417/2021 panaši padermė (b/austria/1359417/2021, bvr-26)/Į b/phuket/3073/2013 panaši padermė (b/phuket/3073/2013, laukinis tipas) - injekcinė suspensija užpildytame švirkšte - 15 µg ha/15 µg ha/15 µg ha/15 µg ha/dozėje - influenza, inactivated, split virus or surface antigen
gefitinib mylan
mylan pharmaceuticals limited - gefitinibas - karcinoma, nesmulkiųjų ląstelių skausmas - antineoplastic agents, protein kinase inhibitors - gefitinib mylan yra nurodyta kaip monotherapy gydyti suaugusiems pacientams su lokaliai išplitusio arba metastazavusio nesmulkialąstelinio plaučių vėžio (nsclc) su ijungtu mutacijas, egfr‑tk.
zenagam
zenthique limited - sugamadekso natrio druska - injekcinis tirpalas - 100 mg/ml - sugammadex